Kymera Therapeutics (NASDAQ:KYMR) Director Bruce Booth Sells 467,878 Shares of Stock

Kymera Therapeutics, Inc. (NASDAQ:KYMR) Director Bruce Booth sold 467,878 shares of the firm’s stock in a transaction on Friday, June 26th. The stock was sold at an average price of $110.29, for a total transaction of $51,602,264.62. Following the completion of the sale, the director owned 472,267 shares of the company’s stock, valued at $52,086,327.43. This trade represents a 49.77% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Bruce Booth also recently made the following trade(s):

• On Monday, June 29th, Bruce Booth sold 45,367 shares of Kymera Therapeutics stock. The stock was sold at an average price of $107.06, for a total transaction of $4,856,991.02.
• On Monday, June 29th, Bruce Booth sold 31,283 shares of Kymera Therapeutics stock. The stock was sold at an average price of $109.48, for a total transaction of $3,424,862.84.
• On Thursday, June 25th, Bruce Booth sold 285,684 shares of Kymera Therapeutics stock. The shares were sold at an average price of $121.86, for a total transaction of $34,813,452.24.
• On Thursday, June 25th, Bruce Booth sold 262,637 shares of Kymera Therapeutics stock. The shares were sold at an average price of $115.39, for a total value of $30,305,683.43.
• On Wednesday, June 24th, Bruce Booth sold 134,720 shares of Kymera Therapeutics stock. The stock was sold at an average price of $100.51, for a total value of $13,540,707.20.
• On Tuesday, June 23rd, Bruce Booth sold 1,408 shares of Kymera Therapeutics stock. The stock was sold at an average price of $99.98, for a total value of $140,771.84.
• On Monday, June 22nd, Bruce Booth sold 246,330 shares of Kymera Therapeutics stock. The shares were sold at an average price of $98.52, for a total value of $24,268,431.60.
• On Thursday, June 18th, Bruce Booth sold 115,056 shares of Kymera Therapeutics stock. The shares were sold at an average price of $91.01, for a total value of $10,471,246.56.
• On Wednesday, June 17th, Bruce Booth sold 105,071 shares of Kymera Therapeutics stock. The stock was sold at an average price of $90.38, for a total value of $9,496,316.98.
• On Wednesday, June 17th, Bruce Booth sold 11,741 shares of Kymera Therapeutics stock. The stock was sold at an average price of $89.98, for a total value of $1,056,455.18.

Kymera Therapeutics Stock Performance

Kymera Therapeutics stock opened at $114.67 on Wednesday. The company has a market cap of $9.43 billion, a P/E ratio of -32.12 and a beta of 2.02. Kymera Therapeutics, Inc. has a one year low of $36.65 and a one year high of $130.05. The business has a fifty day moving average of $85.81 and a two-hundred day moving average of $82.55.

Kymera Therapeutics (NASDAQ:KYMR) last released its quarterly earnings data on Thursday, April 30th. The company reported ($0.71) EPS for the quarter, topping analysts’ consensus estimates of ($0.89) by $0.18. Kymera Therapeutics had a negative net margin of 611.94% and a negative return on equity of 24.71%. The firm had revenue of $34.37 million for the quarter, compared to the consensus estimate of $8.27 million. During the same quarter in the previous year, the firm earned ($0.82) earnings per share. The firm’s revenue was up 55.5% on a year-over-year basis. Sell-side analysts predict that Kymera Therapeutics, Inc. will post -3.28 EPS for the current year.

Analyst Ratings Changes

KYMR has been the subject of several research analyst reports. Jefferies Financial Group assumed coverage on Kymera Therapeutics in a research note on Monday, March 16th. They issued a “buy” rating and a $110.00 price objective for the company. Loop Capital set a $97.00 price target on Kymera Therapeutics in a research report on Monday, June 8th. UBS Group lifted their price target on Kymera Therapeutics from $90.00 to $128.00 and gave the stock a “buy” rating in a research note on Tuesday, March 3rd. Canaccord Genuity Group boosted their price objective on shares of Kymera Therapeutics from $106.00 to $129.00 and gave the stock a “buy” rating in a research report on Friday. Finally, Truist Financial increased their price objective on shares of Kymera Therapeutics from $116.00 to $136.00 and gave the company a “buy” rating in a research note on Monday. One analyst has rated the stock with a Strong Buy rating, twenty-one have given a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $121.41.

Institutional Trading of Kymera Therapeutics

A number of large investors have recently made changes to their positions in the stock. Baker BROS. Advisors LP raised its stake in Kymera Therapeutics by 30.2% in the 4th quarter. Baker BROS. Advisors LP now owns 8,657,242 shares of the company’s stock valued at $673,620,000 after purchasing an additional 2,005,813 shares during the last quarter. Avoro Capital Advisors LLC boosted its stake in shares of Kymera Therapeutics by 17.7% during the 4th quarter. Avoro Capital Advisors LLC now owns 7,474,747 shares of the company’s stock worth $581,610,000 after purchasing an additional 1,124,747 shares during the last quarter. Vanguard Group Inc. boosted its stake in shares of Kymera Therapeutics by 15.6% during the 4th quarter. Vanguard Group Inc. now owns 6,267,644 shares of the company’s stock worth $487,685,000 after purchasing an additional 845,922 shares during the last quarter. Price T Rowe Associates Inc. MD grew its holdings in shares of Kymera Therapeutics by 20.8% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 6,159,335 shares of the company’s stock worth $479,258,000 after buying an additional 1,061,957 shares in the last quarter. Finally, State Street Corp grew its holdings in shares of Kymera Therapeutics by 9.4% during the fourth quarter. State Street Corp now owns 2,209,837 shares of the company’s stock worth $171,947,000 after buying an additional 190,383 shares in the last quarter.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.